Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk will collaborate with PRECISE to analyze whole-genome and other data on 100,000 Singaporeans.

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

The partners will also leverage AI tools and proprietary evaluation models to home in on targetable shared cancer antigens and develop vaccines against them.

Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...

From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized ...

NEW YORK – Fifteen drugs will be offered at a lower cost under Medicare Part D beginning in 2027 after the latest round of drug price negotiations between pharma companies and the Centers for Medicare ...

The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.

The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.